Trump Fast-Tracks Psychedelic Drug for PTSD and Depression

Veterans struggling with PTSD and depression may soon have access to a treatment that's been used successfully in other countries for decades.

President Trump signed an executive order last weekend to fast-track research and approval of ibogaine, a compound extracted from the iboga plant in Central Africa. The move includes $50 million in funding for states to study how the treatment could help people with mental health conditions that haven't responded to traditional approaches.

FDA Commissioner Dr. Marty Makary told CNN the agency could review ibogaine for approval within one to two months once clinical trial data arrives, instead of the usual year-long wait. The FDA granted "investigational new drug" clearance last week, meaning researchers can now ship ibogaine across state lines for the first time in US history.

Dr. Kirsten Cherian, who led a landmark Stanford study on ibogaine, calls the order "a great step" that opens doors for American research facilities. "It is kind of an exciting time," she said.

The compound has been used internationally to treat opioid withdrawal symptoms, reduce drug cravings, and address severe depression, anxiety, and PTSD in veterans. Indigenous communities in Central Africa discovered ibogaine's properties and used it as a sacred medicine for spiritual connection and healing.

American researchers introduced ibogaine as a potential treatment for addiction in 1962 with promising early results. But the DEA classified it as a Schedule I controlled substance in 1967, effectively halting US research for decades. Other countries continued studying and using the treatment while America fell behind.

If approved, ibogaine won't be available at pharmacies. Patients would receive the treatment in hospitals or clinics under close medical supervision, similar to how some cancer treatments are administered.

Why This Inspires

This story represents hope for the millions of Americans whose depression, PTSD, or addiction hasn't improved with current medications. Veterans who've traveled abroad for ibogaine treatment have reported life-changing results, but the cost and travel requirements put it out of reach for most people who need it.

The decision to prioritize mental health treatment research also signals growing recognition that traditional approaches don't work for everyone. When podcast host Joe Rogan shared information about ibogaine with the President, Trump's response was immediate: "Sounds great, do you want FDA approval? Let's do it."

That quick action, backed by serious funding and regulatory changes, means thousands of people suffering right now might have new options sooner than anyone expected.

The breakthrough reminds us that sometimes the most powerful medicines have been hiding in plain sight, waiting for the right moment to reach the people who need them most.